----item----
version: 1
id: {9EB382F4-3A34-4DE9-9AF1-25A55BFDF6B5}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/05/20/Biotie designs SPA with FDA
parent: {9272B77E-1398-4EF1-A77A-17C397C8C6D1}
name: Biotie designs SPA with FDA
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 853a1b84-d6cd-43e5-9b55-f7c7bea25d51

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 116

{07CF1C44-428A-445B-98D8-5EA9905BD7C5}|{3C1D616F-8B3D-44FE-BECC-6DFB88AA7466}|{728904A1-7259-48E8-8256-60D002A0BFEA}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 30

 Biotie designs SPA with FDA  
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 27

Biotie designs SPA with FDA
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1482

<p> <p> Finland Biotech Biotie Therapies has reached an agreement with the FDA regarding the design of its Phase III trial for its Parkinson's disease treatment tozadenant. </p> <p> The late-stage trial will be conducted under a Special Protocol Assessment that will include 450 Parkinson's disease patients over 24 weeks. Patients in the study will receive twice daily doses of wither 60mg of tozadenant, 120mg of tozadenant or placebo. </p> <p> All of the patients in the study are experiencing levodopa related end-of-dose wearing off. While levodopa is one of the most efficacious medications available for Parkinson's patients currently, long-term use of the drug is associated with moto complications and the drug starts to work for shorter and shorter periods of time. Patients often experience an on/off phenomenon where they fluctuate between mobility and immobility. </p> <p> The primary endpoint of the study will be reduced time in the off state for patients. The double-blind portion of the study will be followed by a year of open-label treatment. </p> <p> The Phase III TOZ&mdash;PD trial, along with data from a Phase IIb study, will serve as the basis for a new drug application with the FDA. </p> <p> &quot;The agreement with FDA is another important milestone in our effort to bring tozadenant through the regulatory process and make it available to patients to address a significant unmet medical need,&quot; said Biotie President and CEO Timo Veromaa. </p> <p> 
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 4

<p/>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 27

Biotie designs SPA with FDA
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150520T173205
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150520T173205
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150520T173205
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028832
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 30

 Biotie designs SPA with FDA  
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{2D771726-4AE8-4124-B380-232612225CB7}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

358519
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042351Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

853a1b84-d6cd-43e5-9b55-f7c7bea25d51
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042351Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
